Cancer is one of the leading cause of death worldwide and considered as the second major cause of death after cardiovascular diseases.
The global anticancer drugs market is witnessing a significant growth and is expected to expand at substantial CAGR during the forecast period of 2017–2025. Factors such as the rising prevalence of cancer in many regions, rising awareness towards cancer diagnosis and treatment, introduction of novel pipeline drugs and therapies, rise in cancer awareness programs are expected to have a positive impact on the growth of global anticancer drugs market during the forecast period.
While the global burden of cancer continues to be high, therapeutic innovation based on improved understanding of disease biology and translational research has contributed to the changing paradigm of cancer treatment over the past two decades.
Cancer treatment has seen increased focus on personalized medicine, leading to patient segmentation based on biomarker status. The concept of personalized medicine is now an integral part of clinical practice in oncology, and more clinical trials are stratifying patient populations with predictive biomarkers; this has led to improved clinical outcomes by stratifying patients for their response to treatment. The trend of personalized medicine in oncology has had a positive impact on the drug development process.
Esperer Group is based on principle of “Employee first approach” and extremely dedicated to contribute in advanced Global cancer treatment arena.
Esperer management is well blend of expertise from backward API integration to formulation manufacturing to market faced sales & marketing skills. The team is extremely focused, knowledgeable and having deep aspiration to make a difference in life and society.
In India, we are working towards retaining and growing our position of market leadership in advanced key therapy areas with strong prescription driven hospital sales. We will continue to make considerable investments in product innovation to strengthen our pipeline of affordable niche products for Indian and international markets.
Our international markets now include several emerging country markets in Asia, Africa, South East Asia and part of Europe. We expect the international component of our business to grow significantly in width and depth in the years come.
We are going to be the first Indian company to bring “Cancer-Nutrition product formulation technology patent ” in coming days to improve quality of life of cancer patients as key thrust area in near future.
As employer I look to provide equal employment opportunity and believe in harnessing diversity in our organization. We provide professional development and career advancement to all our employees through our core values of fairness and meritocracy ensuring that we help our people grow with us. We aim to become a top Onco-pharmaceutical company with global-level capabilities serving the bigger need of humanity.
Esperer Bioresearch Pvt. Ltd.
4BA, 4th Floor, Gundecha Onclave
Khairani Road, Sakinaka, Mumbai. 400072
Esperer Bioresearch Pvt Ltd. 123, First Floor, Satra Plaza Premises CHS Ltd. Plot no.19 & 20, Sec - 19D Vashi, Navi mumbai - 400705
Esperer bio-research pvt ltd. 170, first floor, Satra Plaza premises co.op soc ltd. Plot no.19 & 20, Sec - 19D Vashi Navi mumbai - 400705
Esperer Onco Nutrition Pvt Ltd, Biovalley Incubation Council, C/O Andhra Pradesh Medtech zone campus, Pragati Maidan, VM Steel Project SO, Visakhapatnam, 530031